Literature DB >> 24771163

Do optic nerve head and visual field parameters in patients with obstructive sleep apnea syndrome differ from those in control individuals?

R Salzgeber1, M E Iliev1, J Mathis2.   

Abstract

BACKGROUND: It has been suggested that sleep apnea syndrome may play a role in normal-tension glaucoma contributing to optic nerve damage. The purpose of this study was to evaluate if optic nerve and visual field parameters in individuals with sleep apnea syndrome differ from those in controls. PATIENTS AND METHODS: From the records of the sleep laboratory at the University Hospital in Bern, Switzerland, we recruited consecutive patients with severe sleep apnea syndrome proven by polysomnography, apnea-hypopnea index >20, as well as no sleep apnea controls with apnea-hypopnea index <10. Participants had to be unknown to the ophtalmology department and had to have no recent eye examination in the medical history. All participants underwent a comprehensive eye examination, scanning laser polarimetry (GDx VCC, Carl Zeiss Meditec, Dublin, California), scanning laser ophthalmoscopy (Heidelberg Retina Tomograph II, HRT II), and automated perimetry (Octopus 101 Programm G2, Haag-Streit Diagnostics, Koeniz, Switzerland). Mean values of the parameters of the two groups were compared by t-test.
RESULTS: The sleep apnea group consisted of 69 eyes of 35 patients; age 52.7 ± 9.7 years, apnea-hypopnea index 46.1 ± 24.8. As controls served 38 eyes of 19 patients; age 45.8 ± 11.2 years, apnea-hypopnea index 4.8 ± 1.9. A difference was found in mean intraocular pressure, although in a fully overlapping range, sleep apnea group: 15.2 ± 3.1, range 8-22 mmHg, controls: 13.6 ± 2.3, range 9-18 mmHg; p<0.01. None of the extended visual field, optic nerve head (HRT) and retinal nerve fiber layer (GDx VCC) parameters showed a significant difference between the groups.
CONCLUSION: Visual field, optic nerve head, and retinal nerve fiber layer parameters in patients with sleep apnea did not differ from those in the control group. Our results do not support a pathogenic relationship between sleep apnea syndrome and glaucoma. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2014        PMID: 24771163     DOI: 10.1055/s-0034-1368260

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  5 in total

1.  Peripapillary retina nerve fiber layer thickness and macular ganglion cell layer thickness in patients with obstructive sleep apnea syndrome.

Authors:  N Kara; N Sayin; S E Bayramoglu; A U Savas
Journal:  Eye (Lond)       Date:  2017-12-22       Impact factor: 3.775

2.  Evaluation of effects of positive airway pressure treatment on retinal fiber thickness and visual pathways using optic coherence tomography and visual evoked potentials in the patients with severe obstructive sleep apnea syndrome.

Authors:  Melike Batum; Ayşın Kısabay; Hüseyin Mayalı; Tuğba Göktalay; Emin Kurt; Deniz Selçuki; Hikmet Yılmaz
Journal:  Int Ophthalmol       Date:  2020-06-06       Impact factor: 2.031

3.  Ganglion cell layer thickening in patients suffering from Obstructive Sleep Apnea-Hypopnea syndrome with long Mean Apnea-Hypopnea Duration during sleep.

Authors:  Evangelia Chalkiadaki; Konstantinos Andreanos; Efthymios Karmiris; Chrysoula Florou; Xanthi Tsiafaki; Anastasia Amfilochiou; Ilias Georgalas; Chrysanthi Koutsandrea; Dimitrios Papaconstantinou
Journal:  Int Ophthalmol       Date:  2020-11-17       Impact factor: 2.031

4.  Evaluation of Intraocular pressure, Corneal thickness, and Retinal nerve fiber layer thickness in patients with Obstructive Sleep Apnea Syndrome.

Authors:  Kuddusi Teberik; Mehmet Tahir Eski; Ege Gulec Balbay; Murat Kaya
Journal:  Pak J Med Sci       Date:  2018 Jul-Aug       Impact factor: 1.088

5.  Assessment of the retinal nerve fiber layer in individuals with obstructive sleep apnea.

Authors:  Blanca Ferrandez; Antonio Ferreras; Pilar Calvo; Beatriz Abadia; Jose M Marin; Ana B Pajarin
Journal:  BMC Ophthalmol       Date:  2016-04-18       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.